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Abstract The protective effects of high-density lipopro-
tein (HDL) under lipopolysaccharide (LPS) conditions
have been well documented. Here, we investigated
whether an effect of HDL on Toll-like receptor 4
(TLR4) expression and signalling may contribute to its
endothelial-protect i v ee f f e c t sa n dt oi m p r o v e ds u r v i v a li n
a mouse model of LPS-induced inflammation and
lethality. HDL cholesterol increased 1.7-fold (p<0.005)
and lung endothelial TLR4 expression decreased 8.4-fold
(p<0.005) 2 weeks after apolipoprotein (apo) A-I gene
transfer. Following LPS administration in apo A-I gene
transfer mice, lung TLR4 and lung MyD88 mRNA
expression, reflecting TLR4 signalling, were 3.0-fold (p<
0.05) and 2.1-fold (p<0.05) lower, respectively, than in
LPS control mice. Concomitantly, LPS-induced lung
neutrophil infiltration, lung oedema and mortality were
significantly attenuated following apo A–I transfer. In
vitro, supplementation of HDL or apo A–It oh u m a n
microvascular endothelial cells-1 24 h before LPS admin-
istration reduced TLR4 expression, as assessed by
fluorescent-activated cell sorting, and decreased the LPS-
induced MyD88 mRNA expression and NF-κB activity,
independently of LPS binding. In conclusion, HDL
reduces TLR4 expression and signalling in endothelial
cells, which may contribute significantly to the protective
effects of HDL in LPS-induced inflammation and lethality.
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Introduction
Epidemiological studies have shown that high-density
lipoprotein (HDL) cholesterol levels inversely correlate
with the outcome of endotoxic shock [1–3]. Moreover,
systemic administration of reconstituted HDL in human
volunteers down-regulated CD14 on monocytes and
attenuated pro-inflammatory mediators caused by small
doses of intravenous LPS [4]. HDL also protects against
LPS-induced inflammation and lethality in experimental
animal models [5–8]. It has been shown that a twofold
increase of plasma HDL in human apolipoprotein (apo)
A–I transgenic mice enhances the binding of intraperito-
neally administered LPS to HDL, reduces plasma tumour
necrosis factor (TNF)-α levels and improves the survival
rate compared to control mice [5]. Similarly, intravenous
injection of reconstituted HDL increased survival in mice
challenged with LPS [5], as well as in rabbits challenged
with live Escherichia coli [9]. Several in vitro studies
demonstrated that apo A–I, the main apo of HDL, and
sphingosine-1-phosphate (S1P), a sphingolipid associated
with lipoproteins, especially with HDL, inhibit LPS-
induced inflammatory responses. Reconstituted HDL and
an apo A–I mimetic peptide reduced LPS-induced expres-
sion of endothelial cell adhesion molecules in vitro [6, 7].
S1P significantly reduced pulmonary vascular leakage and
inflammation in a murine model of LPS-induced acute
lung injury [8].
Notwithstanding the well-documented anti-inflammatory
effects of HDL and its components during LPS-induced
endotoxemia, a potential direct role of HDL or apo A–Ii n
innate immunity regulation under LPS-induced inflamma-
tion has not yet been investigated. Innate immunity is
characterized by a natural selection of germline-encoded
receptors, which focus the host response to highly
conserved pathogen-associated molecular patterns (PAMPs)
shared by many microorganisms [10, 11]. Toll-like recep-
tors (TLRs), a group of PAMP recognition receptors, play
an important role in innate immune signalling in response
to microbial infection. TLR4 is the main protein involved in
recognizing LPS [12–14] and is of importance in the
pathogenesis of different cardiovascular disorders [15, 16].
Recently, it has been demonstrated that endothelial TLR4
rather than leukocyte TLR4 is the key player in LPS-
induced neutrophil sequestration into lungs and subsequent
lung oedema [17].
Given the well-known endothelial-protective [18–20]
and anti-inflammatory [21, 22] properties of HDL, we
hypothesized in the current study that HDL may attenuate
endothelial TLR4 expression and TLR4 signalling and
improve hereby inflammation and the outcome of LPS-
induced lethality. To explore this hypothesis, we investi-
gated the effect of HDL on TLR4 regulation and TLR4-
mediated signalling in vivo, following human apo A–I gene
transfer in an experimental model of LPS-induced inflam-
mation and lethality. We show that human apo A–I gene
transfer decreases TLR4 expression in vivo in the absence
of LPS and attenuates TLR4 signalling following LPS
administration. Similar effects on TLR4 expression and
TLR4-mediated signalling were induced by HDL in human
microvascular endothelial cells (HMEC)-1 in vitro. These
effects could be mimicked by apo A–I and were observed
independently of LPS binding. These novel endothelial
protective effects of HDL may contribute to increased
survival in this murine model of LPS-induced inflammation
and lethality.
Materials and methods
For detailed methodology, please see the Electronic
supplementary material (ESM) ESM 1 (available online at
http://www.springer.com/biomed/molecular/journal/109). In
brief, 8-week-old male C57BL/6 mice were intravenously
injected with 5×10
10 particles of the E1E3E4-deleted
adenoviral vector Ad.hapoA–I, expressing human apo A–I
[23]. As controls, age-matched C57BL/6 mice were
injected with the same dose of Ad.Null, containing no
expression cassette [23]. Fourteendays hereafter, LPS from
E. coli, serotype 055:B5 (Sigma, Steinheim, Germany), was
intraperitoneally injected at a dose of 80 mg/kg. Mice were
killed 20 h after LPS injection. Lung TLR4 expression as
well as localisation of TLR4 in lung endothelial cells and
neutrophils was determined by immunohistology. In addi-
tion, mRNA expression of lung TLR4, myeloid differenti-
ation factor 88 (MyD88), Toll/IL-1R-containing adaptor
inducing interferon β (TRIF) and ribosomal protein L32
was analysed and lung myeloperoxidase activity was
quantified. In vitro, the effect of pre-incubation with HDL
or its component apo A–Io nT L R 4e x p r e s s i o na n d
signalling was analysed in HMEC-1 cells. Determinations
were performed in the absence or presence of LPS
supplementation following the pre-incubation period. In
the case of LPS, all LPS supplementations were performed
in the absence of HDL or apo A–I to ensure that effects
were independent of LPS binding. The LPS binding
capacity of HDL and apo A–I was also analysed.
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Apo A–I transfer selectively increases HDL cholesterol
both before and after LPS administration
Human apo A–I gene transfer resulted in human apo A–I
levels of 85±4.8 mg/dl at day 14 (ESM Fig. S1A), leading
to 1.7-fold (p<0.005) higher HDL cholesterol levels
compared to Ad.Null controls (Table 1). In agreement with
other reports [24–26], human apo A–I gene transfer
reduced murine apo A–I concentrations 2.8-fold (p<
0.0001) and 2.8-fold (p=0.0005) versus saline-control and
Ad.Null-control mice, respectively (ESM Fig. S1B). Ad.
Null gene transfer did not affect murine apo A–I plasma
levels. Twentyhours after LPS injection, HDL cholesterol
significantly declined in both Ad.Null-LPS and Ad.hapoA-I-
LPS mice, but HDL cholesterol levels in the Ad.hapoA-I-
LPS group were 2.4-fold (p<0.005) higher compared to the
Ad.Null-LPS group (Table 1). Human apo A–I levels
decreased 1.9-fold (p<0.005) after LPS administration
(ESM Fig. S1A). Furthermore, LPS administration resulted
in a 1.3-fold (p<0.05) and 1.5-fold (p<0.05) drop in
murine apo A–I plasma levels in saline and Ad.Null-
injected mice, respectively (ESM Fig. S1B), whereas
murine apo A–I concentrations were not significantly
altered by LPS in Ad.hapoA–I mice. Human apo A–I gene
transfer did not affect non-HDL cholesterol levels (Table 1).
Moreover, the relative content of S1P in HDL was not
influenced by human apo A–I gene transfer (ESM Fig. S2),
which is in agreement with a recent study indicating that
apo A–I is not the determinant protein in HDL responsible
for S1P levels [27]. Since Ad.Null gene transfer did not
alter murine apo A–I plasma levels, nor the cholesterol
lipoprotein profile (ESM Fig. S1C) under control and LPS
conditions, comparisons were consistently performed be-
tween Ad.Null mice and Ad.hapoA–I mice in the majority
of subsequent experiments.
Apo A–I transfer reduces lung TLR4 expression in LPS-
injected mice
Immunohistochemistry identified increased TLR4
expression 20 h after LPS injection in the lungs of Ad.
Null-LPS mice (Fig. 1a). Human apo A–It r a n s f e rd i dn o t
alter lung TLR4 mRNA expression in control mice, but
TLR4 mRNA was 3.0-fold (p<0.05) lower in Ad.hapoA-I-
LPS mice compared to Ad.Null-LPS mice. This Ad.hapoA-
I-induced reduction of TLR4 mRNA expression under LPS
conditions was associated with a 2.1-fold (p<0.05)
decrease in MyD88 mRNA expression, whereas TRIF
mRNA expression declined 1.5-fold (p=NS, Fig. 1b). The
percentage of neutrophils expressing TLR4 increased 1.9-
fold (p<0.05) after LPS administration in control mice,
but this induction was abrogated in Ad.hapoA-I-LPS mice
(Fig. 2).
HDL and apo A–I bind LPS
The effects of human apo A–I transfer on TLR4 expression
after LPS administration may be due to the direct effects of
HDL on TLR4 expression or to LPS binding by HDL or
one of its components. Since the relative content of S1P in
HDL was unchanged after apo A–I gene transfer, suggest-
ing no major S1P-mediated contribution to the effects of
apo A–I transfer on TLR4 signalling, further in vitro
analyses evaluating the effect of S1P were not performed.
We compared the in vitro LPS binding capacity of HDL
and apo A–I using LPS FITC and by evaluating the
fluorescence intensity. ESM Fig. S3 illustrates that both
HDL and apo A–I bind LPS.
HDL reduce endothelial TLR4 expression and signalling
in vivo and in vitro
Considering the critical role of endothelial TLR4 in
neutrophil sequestration in the lungs after LPS adminis-
tration, we investigated the effect of apo A–It r a n s f e ro n
the expression of TLR4 on endothelial cells. Human apo
A–I transfer reduced the percentage of endothelial cells
expressing TLR4 by 8.4-fold (p<0.005) in control mice
(Fig. 3).
To further analyse the effect of HDL and apo A–Io n
endothelial TLR4 expression and TLR4-mediated signal-
ling in vitro, HMEC-1 cells were pre-incubated with HDL
or apo A–I. In the absence of LPS supplementation, TLR4
expression quantified by fluorescent-activated cell sorting
(FACS) was reduced by 2.6-fold (p<0.05) and 2.5-fold (p<
0.01) by pre-incubation with HDL and apo A–I, respec-
Table 1 HDL, non-HDL and total cholesterol
Ad.Null-
Co
Ad.hapoA-I-
Co
Ad.Null-
LPS
Ad.hapoA-I-
LPS
HDL-C (mg/dl) 42±2 73±4** 23±1** 55±2*
,§
Non-HDL-C (mg/dl) 25±2 24±2 40±4** 38±2**
Total-C (mg/dl) 66±3 91±4** 63±5 93±2**
,§
Mouse lipoproteins were separated by density gradient ultracentrifu-
gation as described previously [39]. Fractions were stored at −20°C
until analysis. Cholesterol in lipoprotein fractions was determined
with commercially available enzymes (Roche Diagnostics, Basel,
Switzerland). Precipath L (Roche Diagnostics) was used as a standard.
Data are represented as mean ± SEM
Co control, C cholesterol
*p<0.05; ** p<0.005 (versus Ad.Null-Co);
§p<0.005 (versus Ad.
Null-LPS)
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not altered (Fig. 4b, c). Following the pre-incubation
period, all LPS supplementations were performed in the
absence of HDL or apo A–I to ensure that effects were
independent of LPS binding. LPS supplementation without
pre-incubation with HDL or any of its components
resulted in decreased TLR4 expression (3.5-fold, p<
0.001), whereas MyD88 mRNA expression increased.
Under conditions of pre-incubation with HDL or apo A–
I, the LPS-up-regulated MyD88 mRNA expression was
decreased (Fig. 4b). Concomitantly, pre-incubation with
HDL or apo A–I reduced the LPS-induced p65 NF-κB
activity by 1.6-fold (p<0.05) and 2.0-fold (p<0.05),
respectively (Fig. 4d). Taken together, these results
indicate that HDL may exert direct effects on TLR4
signalling independent of LPS binding.
Apo A–I gene transfer attenuates lipopolysaccharide-
induced lung oedema and endothelial damage
Haematoxylin and eosin staining on paraffin sections dem-
onstratedinterstitialoedema,infiltrationofinflammatorycells
and increased alveolar area in Ad.Null-LPS mice, which was
less pronounced in Ad.hapoA-I-LPS mice (Fig. 5a). The
decrease in pulmonary oedema in Ad.hapoA-I-LPS mice was
also shown by a 1.7-fold (p<0.05) lower wet lung weight/
body weight ratio compared to Ad.Null-LPS mice (Fig. 5b).
In addition, human apo A–I gene transfer significantly
reduced neutrophil infiltration in LPS-treated mice, as
indicated by 1.9-fold (p<0.05) reduced myeloperoxidase
activity and 2.4-fold (p=0.05) decreased density of
myeloperoxidase-positive cells compared to Ad.Null-LPS
mice (Fig. 5c, d). The LPS-induced decrease of endothelial
Fig. 1 Apo A–I transfer reduces
LPS-induced lung TLR4 ex-
pression and signalling. a Rep-
resentative photomicrographs of
Toll-like receptor 4-stained cry-
osections (magnification ×200;
bar corresponds to 100 μm).
Top Baseline TLR4 expression
in a lung of a non-septic
C57BL/6 mouse 14 days after
intravenous injection with Ad.
Null (Ad.Null-Co) or Ad.hapoA-
I (Ad.hapoA-I-Co) and 20 h after
intraperitoneally injected saline
(Ad.Null-Co and Ad.hapoA-I-
Co, respectively). Bottom TLR4
abundance and less pronounced
TLR4 expression in a lung of a
septic C57BL/6 mouse 14 days
after intravenous injection with
Ad.Null or Ad.hapoA-I and 20 h
after intraperitoneally injected
LPS (Ad.Null-LPS and Ad.
hapoA-I-LPS, respectively). Bar
graphs representing lung TLR4
(b), MyD88 (c) and TRIF (d)
mRNA expression, relative to
the Ad.Null-saline group set as
1. Bar graphs indicate mean ±
SEM (n=6), with Ad.Null (open
bars) and Ad.hapoA-I (black
bars). *p<0.05 versus Ad.Null-
LPS,
§p<0.05 versus controls
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hapoA-I-LPS mice than in Ad.Null mice (Fig. 5e).
Apo A–I transfer improves survival in lipopolysaccharide-
induced lethality
To investigate whether human apo A–I gene transfer
may improve LPS-induced lethality, we followed sur-
vival for 60 h. Kaplan–Meier survival curves are shown
in ESM Fig. S4. Comparison of survival curves by
logrank test showed significantly higher survival (p<
0.005) in Ad.hapoA-I-LPS mice compared to saline-LPS
and Ad.Null-LPS mice. No significant difference was
found between the survival rate of Ad.Null-LPS and
saline-LPS mice.
Discussion
This study reveals the reduction of endothelial TLR4
signalling after human apo A–I gene transfer or HDL
supplementation on endothelial cells as a novel endothelial-
protective feature of HDL contributing to the decreased
infiltration of neutrophils and improved survival rate in an
experimental model of LPS-induced inflammation.
Epidemiologicalstudiesdemonstrateaninversecorrelation
between HDL cholesterol concentrations and the outcome of
septic shock [1–3]. In septic patients, the concentrations of
HDL are markedly reduced and the observed changes are
closely related to the severity of the infection [1]. Low serum
concentrations of apo A–I are an independent predictor of
mortality in human sepsis [2, 3]. In contrast to other (apo)
lipoproteins, apo A–I and HDL further decrease in non-
survivors during intensive care unit stay [2]. The current
study shows that an intervention that increases apo A–I
levels improves survival in a mouse model of LPS-induced
inflammation and lethality. This is in agreement with a prior
report which showed that human apo A–I transgenic mice
with elevated apo A–I and twofold higher HDL levels as
control mice are protected against LPS-induced mortality
[5]. These effects may be the direct consequence of
increased plasma apo A–I levels or may be the result of
the quantitative or qualitative changes of HDL. Although
LPS neutralisation by HDL or human apo A–I[ 7] may have
contributed to the in vivo effects of human apo A–It r a n s f e r ,
direct effects of HDL or apo A–I can be postulated. Pre-
incubation of HMEC-1 cells in vitro with HDL or apo A–I
resulted in profound effects on TLR4 signalling after LPS
supplementation in the absence of HDL or apo A–I,
indicating LPS binding-independent effects.
Fig. 2 Apo A–I transfer reduces
LPS-induced lung neutrophil
TLR4 expression. Neutrophil
TLR4 expression in the lung of
C57BL/6 mice 14 days after
intravenous injection with Ad.
Null or Ad.hapoA-I and 20 h
after intraperitoneal injection
with saline or LPS. a Represen-
tative fluorescent microscopy
pictures of double-stained TLR4
(green)/myeloperoxidase (red)
cryosections of (from left to
right) Ad.Null-control, Ad.
hapoA-I-control, Ad.Null-LPS
and Ad.hapoA-I-LPS mice with
below respective phase contrast
pictures (magnification ×1,000;
bar corresponds to 10 μm). b
Bar graph representing percent-
age of neutrophils expressing
TLR4 represented as mean ±
SEM (n=5–7), with Ad.Null
(open bars) and Ad.hapoA-I
(black bars). *p<0.05 versus
Ad.Null-LPS,
§p<0.05 versus
controls
J Mol Med (2011) 89:151–160 155Stimulation or attenuation of inflammation may be
beneficial or detrimental depending on the stage of sepsis.
In this respect, the current model of LPS-induced inflam-
mation and lethality differs from models of sepsis.
Notwithstanding this, intravenous injection of reconstituted
HDL has previously been shown to increase survival in
rabbits challenged with live E. coli [9]. LPS-induced
inflammation and lethality likely corresponds to a stage of
sepsis where reduced inflammation is beneficial. HDL has
generally anti-inflammatory effects, e.g. by inhibiting LPS-
induced CD14 expression on monocytes [5, 9, 28].
Interestingly, Berbée et al. [29] have demonstrated that
plasma levels of apo C–I, an apolipoprotein partially
associated with HDL, are markedly decreased in patients
with severe sepsis. Apo C–I levels were higher in survivors,
even after adjustment for lipid levels [29, 30]. In an
experimental murine study, apo C–I dose-dependently
increased the early inflammatory response to Klebsiella
pneumoniae-induced pneumonia and protected mice against
fatal sepsis [31].
The endothelium plays a crucial role in the pathogenesis
of sepsis: Endothelial cells are the key stromal cell type
involved in innate immune responses to LPS, which recruit
and activate leukocytes to the inflammatory site. Recently,
it has been demonstrated that endothelium-derived rather
than neutrophil-derived TLR4 is the key molecule in LPS-
induced neutrophil sequestration into lungs [17]. This is of
importance since the rapid and selective accumulation of
neutrophils into the lungs is thought to underlie the
pulmonary failure that leads to sepsis-related death. Given
the importance of the endothelium in the pathogenesis of
sepsis and given the endothelial-protective effects of HDL,
we further investigated the regulation of endothelial TLR4
after apo A–I gene transfer in the lung as well as after HDL
supplementation in HMEC-1. Apo A–I transfer reduced
endothelial TLR4 expression in mice before LPS adminis-
tration, indicating an effect of HDL, independent of its LPS
binding capacities. In agreement, supplementation of HDL
or its component apo A–I on HMEC-1 cells reduced TLR4
expression under control conditions, i.e. in the absence of
LPS. Like other cell types, endothelial cells respond to LPS
by the activation of NF-κB[ 32], which in turn induces the
transcription of genes encoding for cytokines and adhesion
molecules [33, 34]. Recent studies have demonstrated that
this effect is mediated through TLR4 [35]. The TLR4-
dependent response to LPS in endothelial cells leads to
induced ICAM-1 and VCAM-1 expression [35]. Under
control conditions, HDL or apo A–I decreased TLR4
expression in the absence of a reduction in NF-κB activity
or a decrease in MyD88 or TRIF mRNA expression. In
contrast, after LPS challenge, a reduction in LPS-induced
NF-κB activity was observed, which was paralleled by a
Fig. 3 Apo A–I transfer
reduces endothelial TLR4 ex-
pression. Endothelial TLR4
expression in the lung of
C 5 7 B L / 6m i c e1 4d a y sa f t e r
intravenous injection with Ad.
Null or Ad.hapoA–I a n d2 0h
after intraperitoneal injection
with saline or LPS. a Repre-
sentative fluorescent microsco-
py pictures of double-stained
TLR4 (green)/von Willebrand
factor (red) cryosections of
(from left to right) Ad.Null-
control, Ad.hapoA-I-control,
Ad.Null-LPS and Ad.hapoA-I-
LPS mice with below respec-
tive phase contrast pictures
(magnification ×1,000; bar
corresponds to 10 μm). b Bar
graph representing per cent of
endothelial cells expressing
TLR4 represented as mean ±
SEM (n=5–7), with Ad.Null
(open bars)a n dAd.hapoA-I
(black bars).
#p<0.05 versus
Ad.Null-control, *p<0.05 ver-
sus Ad.Null-LPS,
§p<0.05 ver-
sus controls
156 J Mol Med (2011) 89:151–160Fig. 4 HDL and its component
apo A–I reduce TLR4 expres-
sion and underlying signalling
in human microvascular endo-
thelial cells-1. Human micro-
vascular endothelial cells-1
(HMEC-1) were incubated in the
presence or absence of HDL
(50 μg/ml) or apo A–I (35 μg/
ml) for 24 h. Next, LPS (100 ng/
ml) was supplemented in the
absence of HDL or apo A–I for
2 h for FACS and mRNA
expression or for 4 h for NF-κB
activity analysis, respectively. a
Bar graph representing per cent
gated cells of n=3 independent
experiments. Right upper panel
Histogram representing counts
of human TLR4 expression in
control, control+apo A–I, con-
trol+HDL and isotype control
(see legend on the right). Right
lower panel Histogram repre-
senting counts of human TLR4
expression in control, LPS and
isotype control (see legend on
the right). Bar graphs represent-
ing MyD88 mRNA expression
(b), TRIF mRNA expression (c)
and p65 NF-κB activity (d),
relative to the normal control
group set as 1. Bar graphs
indicate mean ± SEM (n=4),
with untreated (open bars),
HDL (black bars) and apo A-I
(grey bars).
#p<0.01 versus un-
treated control, *p<0.05 versus
untreated LPS
J Mol Med (2011) 89:151–160 157Fig. 5 Apo A–I transfer attenu-
ates LPS-induced lung damage.
a Representative photomicro-
graphs of haematoxylin and
eosin-stained paraffin sections
(magnification ×200; bar corre-
sponds to 100 μm) from lungs
of control C57BL/6 mice
14 days after intravenous injec-
tion with Ad.Null (Ad.Null-Co)
or Ad.hapoA-I (Ad.hapoA-I-Co,
top) and C57BL/6 mice 20 h
after LPS treatment (Ad.Null-
LPS and Ad.hapoA-I-LPS, bot-
tom). Extensive interstitial oe-
dema, infiltration of
inflammatory cells and haemor-
rhage is present in Ad.Null-LPS
mice, whereas lung damage is
markedly reduced in mice over-
expressing human apo A–I
compared with Ad.Null-LPS
mice. Bar graphs representing
wet lung weight-to-body weight
ratio (b), lung myeloperoxidase
activity (c), as marker of neu-
trophil infiltration, neutrophil
cell density (n/mm
2)( d) and
endothelial cell density (n/mm
2)
(e). Bar graphs indicate mean ±
SEM (n=6), with Ad.Null (open
bars) and Ad.hapoA-I (black
bars). *p<0.05 versus Ad.Null-
LPS,
§p<0.05 versus controls
158 J Mol Med (2011) 89:151–160decrease in MyD88 expression, with MyD88 being the
specific TLR4 signalling pathway in vascular endothelial
cells [36]. HDL did not reduce TRIF mRNA expression,
suggesting a MyD88-specific down-regulation. These
endothelial-protective effects of HDL took place in the
absence of LPS sequestration, underscoring direct effects of
HDL on endothelial TLR4 expression and TLR4 signalling.
Reduced TLR4 signalling likely contributes to a reduction
in ICAM-1 and VCAM-1 expression, leading to decreased
neutrophil infiltration and subsequent less pulmonary
failure in vivo.
Interestingly, despite the LPS-induced abundance of
TLR4 in the lung, a decrease in endothelial TLR4
expression was observed in the lung after LPS challenge.
Also in vitro, LPS reduced endothelial TLR4 expression
on protein level, whereas underlying signalling, the
expression of MyD88 and NF-κB activity, was induced.
This is in line with Yvan-Charvet et al. [37]w h or e c e n t l y
demonstrated LPS-mediated down-regulation of TLR4 in
macrophages in vivo. LPS is rapidly internalized and
transported to the Golgi apparatus [38], suggesting that the
down-regulation of TLR4 can be attributed to co-
localisation and co-internalisation with LPS. Recently, it
has been demonstrated that cholesterol accumulation in the
plasma membrane of ATP-binding cassette transporter
(ABC) G1
−/− and ABCA1
−/−ABCG1
−/− macrophages,
associated with abrogated cholesterol efflux to HDL, leads
to increased levels and signalling of TLR4 and an
increased inflammatory response after exposure to LPS
[37]. Our study, illustrating HDL-mediated down-
regulation of TLR4 expression and signalling, further
supports that there exists a strong link between cellular
cholesterol metabolism and TLR4 signalling.
In summary, our study demonstrates the down-regulation
of endothelial TLR4 as a novel endothelial-protective effect
of HDL, which takes place independently of the LPS
binding capacities of HDL and contributes to the reduced
accumulation of neutrophils in the septic lung, leading to an
improved mortality rate.
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